Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0002013681-25-000001
Filing Date
2025-09-03
Accepted
2025-09-03 15:05:41
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9591
  Complete submission text file 0002013681-25-000001.txt   11526
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Subject) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94447 | Film No.: 251289114
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address OFFICES OF TRICOR SERVICES(BVI) LIMITED, 2/F, PALM GROVE HOUSE, PO BOX 3340, ROAD TOWN, TORTOLA, D8 VG1110
Business Address ROOM 1210-12, 12/F, NAN FUNG TOWER, NO. 88 CONNAUGHT ROAD CENTRAL, CENTRAL, HONG KONG K3 00000 (852)38954913
BC Global Opportunities IX LP (Filed by) CIK: 0002013681 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1224
Type: SCHEDULE 13G